OverviewSuggest Edit

Targovax is a clinical stage immuno-oncology company, which engages in the development of targeted immunotherapies for cancer patients. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company’s product candidates include TG01, which is in Phase I/II clinical trial for the treatment of patients with resected adenocarcinoma of the pancreas; TG02 that is in Phase I clinical trial for the treatment of colorectal cancer; and ONCOS-102 that is in Phase I/II study for the treatment of mesothelioma, as well as for ovarian cancer and soft tissue sarcoma.

TypePublic
HQUllern, NO
Websitetargovax.com

Latest Updates

Employees (est.) (Feb 2019)26(-3%)
Share Price (May 2020)KR7.9 (-1%)

Key People/Management at Targovax

Øystein Soug

Øystein Soug

Chief Executive Officer
Patrick Vink

Patrick Vink

Chief Executive Officer
Erik Digman Wiklund

Erik Digman Wiklund

Board Member
Anne Kirsti Aksnes

Anne Kirsti Aksnes

Chief Financial Officer
Diane Mellett

Diane Mellett

Board Member
Johan Christenson

Johan Christenson

Board Member
Show more

Targovax Office Locations

Targovax has an office in Ullern
Ullern, NO (HQ)
2C Lilleakerveien
Show all (1)

Targovax Financials and Metrics

Targovax Revenue

Market capitalization (29-May-2020)

599.6m

Closing stock price (29-May-2020)

7.9
Targovax's current market capitalization is kr599.6 m.
Show all financial metrics

Targovax Acquisitions / Subsidiaries

Company NameDateDeal Size
Oncos TherapeuticsJuly 02, 2015

Targovax Online and Social Media Presence

Embed Graph

Targovax Blogs

Targovax ASA: Issuance of restricted stock units (RSUs) to the board members

Reference is made to the annual general meeting of Targovax ASA (the “Company”) on 29 April 2020 (the “AGM”) where election of members to the board of directors was according to the nomination committee’s proposal. At the same AGM of the Company the board of directors was authorized to extend the Co…

Targovax ASA: Minutes from the Annual General Meeting

The annual general meeting was held on 29 April 2020 at the Company’s offices at Vollsveien 19, 1366 Lysaker. All proposals on the agenda were approved. Please find minutes of the meeting attached. TRVX – AGM 2020 minutes.pdf For further information, please contact: Renate Birkeli, Investor Relation…

Targovax ASA: Invitation to online presentation of Targovax’s first quarter 2020 results, Thursday 7 May

Oslo, Norway, 29 April 2020 – Targovax ASA (OSE: TRVX) will announce its first quarter 2020 results on Thursday 7 May 2020. An online presentation by Targovax’s management to investors, analysts and the press will take place at 10:00 CET. The results report and the presentation will be available at …

Targovax and Valo Therapeutics enter collaboration to develop RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology

· Targovax and Valo Therapeutics intend to run pre-clinical proof-of-concept studies testing mutant RAS peptide coated ONCOS-102 adenovirus · If successful, the collaboration could lead to further development of a first-in-class mutant-RAS targeting oncolytic virus Oslo, Norway, & Helsinki, F…

Targovax ASA announces proposed new Chairman of the Board

Oslo, Norway, 3 April 2020 – Targovax ASA (OSE: TRVX) announces that its nomination committee has nominated Mr. Damian Marron for election as Chairman of the Board at the company’s Annual General Meeting. Mr. Damian Marron is an experienced non-executive director, corporate advisor and life science …

Targovax ASA: Registration of share capital increase following settlement of restricted stock units

Oslo, 30 March 2020: Reference is made to the stock exchange announcement by Targovax ASA (OSE:TRVX) (“Targovax” or the “Company”) on 26 March 2020, regarding the board of directors’ resolution to increase the share capital of the Company in connection with the settlement of restricted stock units. …
Show more

Targovax Frequently Asked Questions

  • Who are Targovax key executives?

    Targovax's key executives are Øystein Soug, Patrick Vink and Erik Digman Wiklund.

  • How many employees does Targovax have?

    Targovax has 26 employees.

  • Who are Targovax competitors?

    Competitors of Targovax include Pantherna Therapeutics, Medicenna Therapeutics and Fab'entech.

  • Where is Targovax headquarters?

    Targovax headquarters is located at 2C Lilleakerveien, Ullern.

  • Where are Targovax offices?

    Targovax has an office in Ullern.

  • How many offices does Targovax have?

    Targovax has 1 office.